Drug Profile
Research programme: infectious diseases therapeutics - Abivax
Alternative Names: ABX 202; ABX 221; ABX 309; ABX 311; ABX 544Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Abivax
- Class Antivirals; Polyclonal antibodies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chikungunya virus infections; Dengue
- Discontinued Ebola virus infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Chikungunya-virus-infections in France
- 28 Oct 2020 No recent reports of development identified for research development in Dengue in France
- 26 Mar 2020 Discontinued for Ebola virus infections in France (Parenteral) (Abivax pipeline, March 2020)